Other News To Note
Wednesday, February 15, 2012
Gene Signal International SA, of Lausanne, Switzerland, published data in Investigative Ophthalmology & Visual Science demonstrating the activity of aganirsen (GS-101, eye drops) in two models of retinal neovascular disease, wet age-related macular degeneration and ischemic retinopathy. Aganirsen is an antisense oligonucleotide that is expected to complete a Phase III trial in progressive neovascularization in the cornea this year. The data demonstrated the ability of aganirsen to reach and exert activity on the retina.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.